Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedApr 22, 2026
DataAggregated Company Financials
Companies20
  • 7D0.3%
  • 3M-29.5%
  • 1Y-30.1%
  • YTD-22.3%

Over the last 7 days, the Healthcare industry has remained flat, although notably Genmab declined by 6.0%. As for the longer term, the industry has declined 30% in the last year. As for the next few years, earnings are expected to grow by 3.8% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 22 Apr 2026DKK 1.5tDKK 447.3bDKK 129.9b19.7x11.7x3.4x
Fri, 20 Mar 2026DKK 1.5tDKK 447.6bDKK 130.0b16.3x11.2x3.2x
Sun, 15 Feb 2026DKK 1.8tDKK 448.0bDKK 134.8b15.7x13.5x4.1x
Tue, 13 Jan 2026DKK 2.2tDKK 453.9bDKK 136.9b18x16x4.8x
Thu, 11 Dec 2025DKK 1.9tDKK 454.0bDKK 137.0b17.1x13.7x4.1x
Sat, 08 Nov 2025DKK 1.8tDKK 451.6bDKK 134.3b17.6x13.2x3.9x
Mon, 06 Oct 2025DKK 2.2tDKK 447.3bDKK 141.7b18.3x15.5x4.9x
Wed, 03 Sep 2025DKK 2.1tDKK 447.5bDKK 141.8b23.9x14.6x4.6x
Fri, 01 Aug 2025DKK 1.8tDKK 423.9bDKK 124.7b29.2x14.8x4.4x
Sun, 29 Jun 2025DKK 2.4tDKK 423.1bDKK 124.5b30.5x19.2x5.7x
Tue, 27 May 2025DKK 2.5tDKK 424.3bDKK 125.1b25.1x20x5.9x
Thu, 24 Apr 2025DKK 2.3tDKK 409.3bDKK 121.3b21.6x18.7x5.5x
Sat, 22 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.7x23.4x6.9x
Mon, 17 Feb 2025DKK 3.0tDKK 409.9bDKK 121.5b26.3x24.9x7.4x
Wed, 15 Jan 2025DKK 3.2tDKK 387.5bDKK 111.3b28.9x28.6x8.2x
Fri, 13 Dec 2024DKK 4.0tDKK 387.4bDKK 111.3b30.8x36.1x10.4x
Sun, 10 Nov 2024DKK 3.9tDKK 386.3bDKK 110.7b32.7x35.1x10.1x
Tue, 08 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.3x38.6x11.1x
Thu, 05 Sep 2024DKK 4.6tDKK 371.9bDKK 107.2b35.3x43.2x12.4x
Sat, 03 Aug 2024DKK 4.5tDKK 355.3bDKK 106.3b36.6x42x12.6x
Mon, 01 Jul 2024DKK 5.0tDKK 355.3bDKK 106.2b35.1x47.4x14.2x
Wed, 29 May 2024DKK 4.6tDKK 355.3bDKK 106.2b37.2x43.6x13x
Fri, 26 Apr 2024DKK 4.4tDKK 341.4bDKK 99.6b32.8x44.3x12.9x
Sun, 24 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.7x45.7x13.4x
Tue, 20 Feb 2024DKK 4.4tDKK 340.0bDKK 98.7b34.9x44.7x13x
Thu, 18 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.5x42.1x11.8x
Sat, 16 Dec 2023DKK 3.5tDKK 320.5bDKK 90.0b32.9x38.7x10.9x
Mon, 13 Nov 2023DKK 3.6tDKK 319.8bDKK 89.9b31.7x39.6x11.1x
Wed, 11 Oct 2023DKK 3.4tDKK 305.5bDKK 82.2b34.2x41.7x11.2x
Fri, 08 Sep 2023DKK 3.6tDKK 305.5bDKK 82.2b36.3x43.3x11.6x
Sun, 06 Aug 2023DKK 2.9tDKK 288.2bDKK 74.9b38.5x38.6x10x
Tue, 04 Jul 2023DKK 3.0tDKK 287.1bDKK 75.5b39.7x39.3x10.3x
Thu, 01 Jun 2023DKK 3.1tDKK 287.2bDKK 75.5b41x40.6x10.7x
Sat, 29 Apr 2023DKK 3.1tDKK 272.6bDKK 69.0b44.7x45.1x11.4x
Price to Earnings Ratio

45.1x


Total Market Cap: DKK 3.1tTotal Earnings: DKK 69.0bTotal Revenue: DKK 272.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 31.2x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.7x which is lower than its 3-year average PE of 31.2x.
  • The 3-year average PS ratio of 8.9x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 23% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-0.31%
Healthcare0.30%
Life Sciences3.31%
Medical Equipment1.66%
Healthtech0.84%
Pharma0.70%
Biotech-4.71%
Healthcare Services-5.59%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 569x.
    • Analysts are expecting annual earnings growth of 87.6%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 88% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 6.3% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ALK B ALK-AbellóDKK 228.606.9%
+DKK 3.3b		54.9%PE42.3x
HLUN B H. LundbeckDKK 43.123.7%
+DKK 1.5b		46.1%PE13.4x
ZEAL Zealand PharmaDKK 306.002.0%
+DKK 430.8m		-24.6%PE3.3x
DEMANT DemantDKK 215.000.7%
+DKK 337.4m		-6.8%PE19.1x
CHEMM ChemoMetecDKK 343.203.8%
+DKK 219.3m		-28.5%PE33.7x

Latest News

BAVA
DKK 192.50
Bavarian Nordic
7D
-4.0%
1Y
25.6%
NOVO B
DKK 249.45
Novo Nordisk
7D
-1.0%
1Y
-39.0%
ALK B
DKK 228.60
ALK-Abelló
7D
6.9%
1Y
54.9%
CHEMM
DKK 343.20
ChemoMetec
7D
3.8%
1Y
-28.5%
AMBU B
DKK 68.45
Ambu
7D
1.0%
1Y
-41.0%

AMBU B: Reset P/E Assumptions Will Support Future Upside Repricing

Ambu's analyst price target has been reduced by DKK 12 to reflect updated views on its P/E assumptions, revenue growth profile and profitability, with analysts pointing to the recent DKK 12 target cut cited in Street research. Analyst Commentary JPMorgan's DKK 12 reduction in its Ambu price target reflects a reset of P/E expectations and a more cautious stance on the company's revenue growth and profitability profile.
HLUN B
DKK 43.12
H. Lundbeck
7D
3.7%
1Y
46.1%

HLUN B: Dividend Policy And Neuroscience Pipeline Will Support Balanced Medium Term Outlook

Analysts have kept their DKK 46.13 price target for H. Lundbeck unchanged, citing consistent assumptions about revenue growth, profit margins and future P/E as the basis for their view.
EMBLA
DKK 28.10
Embla Medical hf
7D
0.4%
1Y
5.2%
ZEAL
DKK 306.00
Zealand Pharma
7D
2.0%
1Y
-24.6%
GMAB
DKK 1,770.00
Genmab
7D
-3.8%
1Y
33.1%

GMAB: 2026 Clinical Readouts And AI Use Will Shape Outlook

Genmab's updated analyst price target edges slightly lower to DKK 2,233 from DKK 2,238, as analysts factor in mixed views around Epkinly assumptions, acquisition driven pipeline updates, and a modestly higher future P/E expectation despite broadly constructive long term growth potential. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the expanded pipeline and upcoming catalysts, alongside caution tied to Epkinly assumptions and valuation.
GUBRA
DKK 331.60
Gubra
7D
-3.8%
1Y
-8.2%

GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside

Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).
COLO B
DKK 421.60
Coloplast
7D
-2.8%
1Y
-41.2%

COLO B: New CEO Appointment Will Support Future Re Rating Potential

The updated analyst price target for Coloplast has been reduced by DKK 6.53. This change reflects a slight reset in fair value as analysts incorporate higher discount rates, marginally softer margin assumptions, and recent price target cuts, along with mixed rating changes across the Street.
SMSMED
DKK 2.97
Scandinavian Medical Solutions
7D
-10.8%
1Y
-29.6%
DEMANT
DKK 215.00
Demant
7D
0.7%
1Y
-6.8%

DEMANT: Recent Upgrades And 2026 Guidance May Support Re Rating

The updated analyst price target for Demant now sits at DKK 232, up modestly from DKK 232. The small adjustment reflects a mix of recent upgrades and price target cuts as analysts reassess assumptions for discount rates, revenue growth, profit margins and future P/E levels.
VIRO
DKK 11.00
ViroGates
7D
-0.9%
1Y
71.3%
PEG
DKK 0.099
Pharma Equity Group
7D
23.5%
1Y
16.5%
MONSO
DKK 0.15
Monsenso
7D
-1.3%
1Y
-49.7%